Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis | Zendy

Yasuo Suzuki | Zendy; Mamoru Watanabe | Zendy; Toshiyuki Matsui | Zendy; Satoshi Motoya | Zendy; Tadakazu Hisamatsu | Zendy; Hirotoshi Yuasa | Zendy; Junichi Tabira | Zendy; Naoki Isogawa | Zendy; Shinichi Tsuchiwata | Zendy; Shoko Arai | Zendy; Toshifumi Hibi∥ | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis

Author(s) -

Yasuo Suzuki,

Mamoru Watanabe,

Toshiyuki Matsui,

Satoshi Motoya,

Tadakazu Hisamatsu,

Hirotoshi Yuasa,

Junichi Tabira,

Naoki Isogawa,

Shinichi Tsuchiwata,

Shoko Arai,

Toshifumi Hibi∥

Publication year - 2019

Publication title -

inflammatory intestinal diseases

Language(s) - English

Resource type - Journals

eISSN - 2296-9403

pISSN - 2296-9365

DOI - 10.1159/000502144

Subject(s) - tofacitinib , medicine , ulcerative colitis , placebo , gastroenterology , janus kinase inhibitor , adverse effect , clinical endpoint , population , clinical trial , rheumatoid arthritis , alternative medicine , disease , environmental health , pathology

Tofacitinib is an oral, small molecule Janus kinase inhibitor approved in Japan for the treatment of ulcerative colitis (UC). Differences in the safety profile of tofacitinib in Japanese patients versus the global population, such as a higher risk of herpes zoster, have been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research